



Please see relevant highlighted text on page 2

This site uses cookies. More info   Close By continuing to browse the site you are agreeing to our use of cookies. [Find out more here](#) Close

Analysis

Should people at low risk of cardiovascular disease take a statin?

BMJ 2013; 347 doi: <http://dx.doi.org/10.1136/bmj.f6123> (Published 22 October 2013) Cite this as: BMJ 2013;347:f6123

- [Article](#)
- [Related content](#)
- [Article metrics](#)
- [Rapid responses](#)
- [Response](#)

Re: Should people at low risk of cardiovascular disease take a statin?

Dear Dr. Godlee,

The BMJ Analysis of statins in low risk people stated, “the evidence does not show that the benefits of statins in low risk patients outweigh the harms and that the advice for treatment of this group should not be changed.”(1) Our Cochrane systematic review on statins for the primary prevention of cardiovascular disease (CVD) is criticized for not coming to the same conclusion.(2) Readers of the BMJ may be interested in our views on their arguments.

The timing of this Analysis predated by three weeks the publication of the 2013 American College of Cardiology/American Heart Association cholesterol treatment guidelines (November 12, 2013), but statements were made about “proposed standards” without full knowledge of these guidelines. Notably, none of the authors were acknowledged reviewers of the ACC/AHA guidelines.(3)

Abramson et al. state: "Under the proposed 2013 standards, however, no level of risk would preclude statin therapy, raising the question whether all people over the age of 50 should be treated." Neither the Cochrane review nor the ACC/AHA cholesterol guidelines proposed treatment for everyone over the age of 50 years. The ACC/AHA guidelines recommends that initiation of moderate-intensity statin therapy be considered for patients with predicted 10-year “hard” ASCVD risk of 5.0% to <7.5%.” The Cochrane review questioned the feasibility and desirability of having to treat the majority of people over the age of 50 years with a statin.

These authors comment that the inclusion of four additional trials“ did not substantially alter the previously documented effect of statin therapy”. The updating of the evidence base resulted in an expected narrowing of confidence intervals and the addition of JUPITER trial added important evidence on diabetes risk.

The authors consider that statins should reduce total mortality if they are to have a place in primary prevention in people in lower CVD risk strata and estimate a relative risk of 0.95, 95% confidence interval 0.86 to 1.04. However, the authors included both individuals with and without prior vascular disease in this estimate. In our Table we have conducted the appropriate analysis using only low-risk individuals (<5%, 5-10%) without prior vascular disease. In the lowest risk category (<5%), the number of total deaths was small (1% of control group participants dying over 4 years) and non-CVD causes of death exceeded CVD deaths by more than 2:1. However, the risk of suffering a major vascular event (fatal and non-fatal) was 0.6% per year, which was reduced by statins (RR 0.62 [95%CI 0.47, 4.81]; 167 events on statin vs. 254 events on control; similar effect

size across major coronary event, stroke, and revascularization) in this low risk group (Figure 1, Cholesterol Treatment Trialists' 2012 Lancet paper(4)). No strong evidence of benefit for total mortality was seen because other causes of death make up a greater proportion of total deaths, and it is unlikely that taking statins influences these non-CVD deaths.

We disagree with their statement that the “best indication of the net effect of a treatment on overall health is the total number of serious adverse events — which include deaths from all causes, hospital admissions, prolongations of admission, cancer, or permanent disability.” Weighting each of these events similarly is incorrect. Deaths, disability, and prolongation of admission are quite different outcomes that would not be weighted similarly by most patients.(5)

While criticizing the RCTs, they use low quality evidence from observational studies to support their statements about the hazards associated with statins despite likely high risk of bias. The authors also conflate muscle pain (myalgias), an important side effect of statins, with myopathy, a rare and more serious problem, both of which warrant ongoing study. The authors cite studies demonstrating adverse events associated with statin therapy but fail to cite systematic reviews which show no increased risk of psychological outcomes, fractures, acute renal failure, arthritis, or venous thromboembolism.(6-9) The incidence of diabetes appears to be real but is linked to the underlying risk of developing diabetes among participants and is also associated with the intensity of statin dose.

Finally, Abramson et al. set up a false dichotomy, stating: “Rather than being compelled by guidelines to prescribe statin therapy for people at low risk of cardiovascular disease, doctors would provide a far greater service by explaining the magnitude of the benefits and uncertainty about the harms of statins together with discussion of the epidemiological evidence showing that behavioural risk factors—including tobacco use, lack of physical exercise, and unhealthy diet—are responsible for 80% of cardiovascular disease.” If they (and the BMJ editors) had awaited the publication of the 2013 ACC/AHA cholesterol guidelines, they would have been directed to the companion lifestyle guidelines, which aim to address these topics. Salient comment on the importance of considering benefits, harms, alternative non-pharmacological treatments are embedded in the relevant section of the report. Strong evidence to support the benefits of the type of health promotion proposed by Abramson et al. in CVD primary prevention is sadly lacking.

We have outlined several flaws in the Abramson and colleagues “Analysis”, which we believe threaten its validity. The decision for patients at low risk for CVD to initiate or continue statin therapy for primary prevention remains under the purview of patients and their physicians. We hope that our Cochrane review, which will continue to be updated as further evidence accrues, will help inform those conversations for better decision-making and better health.

Regards,

Mark Huffman, MD, MPH
Departments of Preventive Medicine and Medicine-Cardiology
Northwestern University Feinberg School of Medicine
Chicago, USA

Fiona C. Taylor, PhD
Department of Noncommunicable Disease Epidemiology
London School of Hygiene and Tropical Medicine
London, United Kingdom

Shah Ebrahim, DM
Department of Noncommunicable Disease Epidemiology

London School of Hygiene and Tropical Medicine
London, United Kingdom

REFERENCES

1. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? *BMJ* 2013; 347:f6123. doi: 10.1136/bmj.f6123
2. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2013; 1:CD004816. doi:10.1002/14651858.CD14004816.pub14651855.
3. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith Jr SC, Levy D, Watson K, Wilson PWF, 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. *J Am Coll Cardiol* 2013; in press. doi:10.1016/j.jacc.2013.11.002.
4. Cholesterol Treatment Trialists' Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012; 380:581-590. doi:10.1016/S0140-6736(12)60367-5
5. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies. the story of major adverse cardiac events and percutaneous coronary intervention. *J Am Coll Cardiol* 2008;51(7):701-707. doi:10.1016/j.jacc.2007.10.034
6. O'Neil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams LJ, Pasco JA, Berk M. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. *BMC Med* 2012; 10:154 doi:10.1186/1741-7015-10-154
7. Toh S, Hernández-Díaz S. Statins and fracture risk. A systematic review. *Pharmacoepidemiol Drug Saf* 2007; 16:627-40.
8. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. *J Am Soc Nephrol* 2006; 17:2006-16.
9. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, Robertson M, Wikstrand J, McMurray J. Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. *PLoS Med* 2012; 9: e1001310. doi:10.1371/journal.pmed.1001310

Competing interests: Dr Huffman reports receiving grant funding from the National Heart, Lung, and Blood Institute and AstraZeneca and travel support from AstraZeneca. Dr Ebrahim reports receiving grant funding from Wellcome Trust and the National Institute of Health Research and royalties from Open University Press.

- [BMJ Rapid Response Table v27Nov2013.pdf](#)

27 November 2013

Mark D Huffman

Assistant professor of preventive medicine and medicine-cardiology

Drs. Fiona Taylor and Shah Ebrahim, London School of Hygiene and Tropical Medicine

Northwestern University Feinberg School of Medicine

680 N. Lake Shore Drive, Suite 1400

Click to like:

25

